Journal
CLINICA CHIMICA ACTA
Volume 444, Issue -, Pages 81-85Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.cca.2015.01.039
Keywords
EGFR; T790M; Mutation; Resistance; Non small-cell lung cancer
Categories
Ask authors/readers for more resources
Lung cancer patients carrying sensitive epidermal growth factor receptor (EGFR) mutations show dramatic responses to tyrosine kinase inhibitors (TKIs). However, the majority of patients whose disease responds to drugs eventually develop resistance to these EGFR-TKIs. The T790M gatekeeper mutation in the EGFR tyrosine kinase domain accounts for half of resistance to these drugs. In some patients, this mutation is also detected as a primary event before drug exposure, at a frequency that is highly dependent on the technique used. This review will focus on the methods that have been used to detect the T790M mutation, and its potential clinical applications both in TKI naive patients and in patients with an acquired resistance. (C) 2015 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available